Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKPSIA)

Drug Name
Heterocyclic derivative 8 Drug Info
Synonyms PMID25684022-Compound-US20120208819 5(355)
Indication
Disease Entry ICD 11 Status REF
Metastatic cancer 2D50-2E2Z Patented [1]
Solid tumour/cancer 2A00-2F9Z Patented [1]
Cross-matching ID
TTD Drug ID
DMKPSIA

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Pyruvate dehydrogenase kinase 1 (PDHK1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dichloroacetate DMZ5Y1P Insulin-resistant disorder 5A44 Phase 4 [2]
Heteroaryl-carboxamide derivative 4 DMHUIXR Metastatic cancer 2D50-2E2Z Patented [1]
Pyrazole derivative 61 DMO6M1Q Metastatic cancer 2D50-2E2Z Patented [1]
PMID25684022-Compound-WO2011137219 37(4-6) DMSQ5J8 Metastatic cancer 2D50-2E2Z Patented [1]
Heteroaryl-carboxamide derivative 3 DMBGTNM Metastatic cancer 2D50-2E2Z Patented [1]
Pyrimidine derivative 3 DMC3E8M Metastatic cancer 2D50-2E2Z Patented [1]
Heterocyclic derivative 15 DMWZNDO Metastatic cancer 2D50-2E2Z Patented [1]
Thieno[3,2-c]pyridine-7-carboxamide derivative 2 DMOWFA5 Metastatic cancer 2D50-2E2Z Patented [1]
Heteroaryl-carboxamide derivative 9 DMI627Z Metastatic cancer 2D50-2E2Z Patented [1]
Thiazole carboxamide derivative 24 DMZ6YB0 Metastatic cancer 2D50-2E2Z Patented [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Pyruvate dehydrogenase kinase 1 (PDHK1) TTCZOF2 PDK1_HUMAN Inhibitor [1]

References

1 PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
2 Comparison of Antitumor Effects of Combined and Separate Treatment with NO Synthase Inhibitor T1023 and PDK1 Inhibitor Dichloroacetate. Bull Exp Biol Med. 2019 Nov;168(1):92-94.